Advertisement
Australia markets closed

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • AUD/USD

    0.6500
    +0.0011 (+0.17%)
     

  • OIL

    82.94
    -0.42 (-0.50%)
     

  • GOLD

    2,334.70
    -7.40 (-0.32%)
     

  • Bitcoin AUD

    101,786.16
    -930.37 (-0.91%)
     

  • CMC Crypto 200

    1,429.87
    +5.77 (+0.41%)
     

  • AUD/EUR

    0.6074
    +0.0017 (+0.28%)
     

  • AUD/NZD

    1.0951
    +0.0021 (+0.19%)
     

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NASDAQ

    17,628.73
    +157.26 (+0.90%)
     

  • FTSE

    8,061.26
    +16.45 (+0.20%)
     

  • Dow Jones

    38,523.03
    +19.34 (+0.05%)
     

  • DAX

    18,126.54
    -11.11 (-0.06%)
     

  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

What's in Store for CDW Corp (CDW) This Earnings Season?

Zacks Equity Research
·3-min read

CDW Corporation CDW is set to report second-quarter 2020 results on Aug 5.

The Zacks Consensus Estimate for quarterly revenues is pinned at $4.32 billion, indicating a 6.7% year-over-year decline. The consensus mark for earnings is pegged at $1.35 per share, suggesting a 15.6% decrease, year on year.

The company’s earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and came in line in the other, the average surprise being 5.1%.

CDW Corporation Price and Consensus

CDW Corporation Price and Consensus
CDW Corporation Price and Consensus

CDW Corporation price-consensus-chart | CDW Corporation Quote

 

Let’s see how things have shaped up for the upcoming announcement.

Factors at Play

CDW’s second-quarter results are likely to have been adversely impacted by the pandemic-induced business disruptions. Lower IT spending as organizations are pushing back their investments in big and expensive technology products, due to the global economic slowdown concerns amid the coronavirus crisis, is expected to have hurt the firm’s quarterly performance.

ADVERTISEMENT

Nonetheless, the coronavirus-induced demand for advanced IT-service infrastructure solutions for remote working and digital healthcare services is anticipated to have positively impacted the company’s performance during the quarter under review.

CDW’s strategy to supplement organic growth, alongside acquisitions, is also anticipated to have strengthened the company profile significantly. The firm’s buyouts of Aptris and Scalar Decisions have been instrumental in enhancing its capabilities to solve customers’ business problems. This makes us optimistic about the upcoming results.

What Our Model Says

Our proven model does not predict an earnings beat for CDW this season. The combination of a positive Earnings ESP, and Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell, before they’re reported, with our Earnings ESP Filter.

CDW currently carries a Zacks Rank of 4 (Sell) and has an Earnings ESP of +0.48%.

Stocks With Favorable Combinations

Here are some companies, which, per our model, have the right combination of elements to post an earnings beat this quarter:

Cogent Communications Holdings CCOI has an Earnings ESP of +11.66% and carries a Zacks Rank of 2, at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Synaptics SYNA has an Earnings ESP of +10.6 % and currently carries a Zacks Rank of 2.

Benefitfocus BNFT has an Earnings ESP of +6.25% and carries a Zacks Rank of 2, currently.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Synaptics Incorporated (SYNA) : Free Stock Analysis Report
 
Cogent Communications Holdings, Inc. (CCOI) : Free Stock Analysis Report
 
CDW Corporation (CDW) : Free Stock Analysis Report
 
Benefitfocus, Inc. (BNFT) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.